Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis

Total dose, fraction dose and respiratory motion management impact adrenal SBRT outcome

“…In our study of 83 patients, adrenal SBRT demonstrated promising local control with only mild toxicity. We achieved a two-year local control rate of 76.4 %, which compares favorably to other published studies [14] .…”

“…While König et al detected a non-significant trend for improved local control, a BED ≥ 75.0 Gy. A recent meta-analysis by Franzese et al concluded that a BED > 72 Gy combined with using 4DCT for motion control should be considered for high-quality ablative adrenal SBRT [9] , [14] . Additionally, a multicenter database analysis indicated that achieving a significant improvement in Local Recurrence Rate (LRR) for adrenal SBRT necessitates a BED > 73.2 Gy (adenocarcinoma: 69.1 Gy) [15] .…”

Multi-institutional experience of MR-guided stereotactic body radiation therapy for adrenal gland metastases

“…Following MRgSBRT to a median BED 10 of 100 Gy (range 48–132 Gy), we demonstrate a 1-year LC rate of 92 % ( Fig. 1 A), which compares favorably to the literature (66–100 %) [8] , [9] , [10] , [11] , [12] , [13] , [24] , [25] , [26] , [27] , [28] . Though the present study did not demonstrate a significant effect of SBRT dose upon LC, this was likely due to a limited sample size and limited BED variations, as multiple prior studies have found increased dose predictive of improved LC [13] , [25] , [26] .…”

“…Though SBRT has emerged as a relatively safe, non-invasive, and effective treatment for AGMs, LC following SBRT is quite variable and significantly influenced by dose (1-year LC 66–100 %) [8] , [9] , [10] , [11] , [12] , [13] , [24] , [25] , [26] , [27] , [28] . However, the proximity of GI OARs often limits the SBRT dose that can be safely prescribed to an AGM, particularly on the left side due to the stomach, large, and small bowel.…”

Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update

“…These observations demonstrated the superior trend in treatment response in groups with a higher biologically effective dose (BED; ≥75 Gy); further studies are needed to confirm these results. Notably, by analyzing tumors based on volume, other studies have also reported comparable control rates for adrenal metastases by SBRT [ 69 , 70 ]. Some ongoing trials are current testing the effects of SBRT on oligometastatic NSCLC including adrenal oligometastases ( Table 2 ).…”